These are the conditions for funding in the respective
province and territory:
NOVA SCOTIA
On December 1, 2016, Nova Scotia will begin provincially funding Revlimid. The funding criteria is as follows:
Lenalidomide as an option for first line treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment is in combination with dexamethasone for patients with an ECOG performance status of less than or equal to 2 and continued until disease progression.
This information is publicly available on their website
HERE
THE YUKON
As of November 8, 2016, the Yukon will begin funding Revlimid. The funding criteria is as follows:
Lenalidomide as an option for first line treatment in patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment should be in combination with dexamethasone for patients with ECOG performace statuts of less than or equal to 2 and continued until disease progression.
This information is publicly available on their website HERE
|